A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Inclusion criteria

• Have Body Mass Index (BMI) at screening of the following:

• 30 kilogram per square meter (kg/m2) OR
• 27 kg/m2 with at least one of the following weight-related health conditions at screening:

• high blood pressure
• dyslipidemia
• obstructive sleep apnea, or
• heart disease
• Have a stable body weight (<5% body weight change) for 90 days prior to screening.
• Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight

Exclusion criteria

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
• Have type 1 diabetes or type 2 diabetes
• Have had within 90 days prior to screening:

• heart attack
• stroke
• coronary artery revascularization
• unstable angina, or
• hospitalization due to congestive heart failure
• Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
• Have taken medications or alternative remedies intended for weight loss within 90 days of screening